Financial Summary (All financials)
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
Revenues | 17,652.0 | 16,802.0 | 13,834.0 | 15,146.0 | 15,374.0 | 14,748.0 | 0.0 | 14,241.0 |
Revenue growth | 5.1% | 21.5% | -8.7% | -1.5% | 4.2% | | -100.0% | -3.7% |
Cost of goods sold | 11,096.0 | 10,286.0 | 7,777.0 | 8,653.0 | 9,001.0 | 8,209.0 | 7,665.0 | 7,786.0 |
Gross profit | 6,556.0 | 6,516.0 | 6,057.0 | 6,493.0 | 6,373.0 | 6,539.0 | -7,665.0 | 6,455.0 |
Gross margin | 37.1% | 38.8% | 43.8% | 42.9% | 41.5% | 44.3% | | 45.3% |
Selling, general and administrative | 3,842.0 | 3,780.0 | 3,389.0 | 3,604.0 | 3,573.0 | 3,554.0 | 3,555.0 | 3,584.0 |
Research and development | 448.0 | 439.0 | 379.0 | 432.0 | 441.0 | 451.0 | 453.0 | 466.0 |
EBITA | 1,751.7 | 1,962.0 | 1,721.0 | 1,836.0 | 1,740.0 | 2,069.0 | 902.0 | 1,989.0 |
EBITA margin | 9.9% | 11.7% | 12.4% | 12.1% | 11.3% | 14.0% | | 14.0% |
Amortization of intangibles | 166.0 | 172.0 | 138.0 | 136.0 | 143.0 | 129.0 | 121.0 | 132.0 |
EBIT | 1,585.7 | 1,790.0 | 1,583.0 | 1,700.0 | 1,597.0 | 1,940.0 | 781.0 | 1,857.0 |
EBIT margin | 9.0% | 10.7% | 11.4% | 11.2% | 10.4% | 13.2% | | 13.0% |
Pre-tax income | 1,361.7 | 1,815.0 | 1,362.0 | 1,661.0 | 1,693.0 | 2,005.0 | 779.0 | 1,745.0 |
Income taxes | 325.0 | 374.0 | 291.0 | 392.0 | 353.0 | 615.0 | 214.0 | 413.0 |
Tax rate | 23.9% | 20.6% | 21.4% | 23.6% | 20.9% | 30.7% | 27.5% | 23.7% |
Earnings from continuing ops | 1,036.7 | 1,420.0 | 1,056.0 | 1,243.0 | 1,323.0 | 1,369.0 | 543.0 | 1,311.0 |
Earnings from discontinued ops | 0.0 | 19.0 | 3.0 | | 18.0 | 225.0 | 330.0 | 95.0 |
Net income | 1,026.0 | 1,439.0 | 1,059.0 | 1,243.0 | 1,341.0 | 1,594.0 | 873.0 | 1,406.0 |
Net margin | 5.8% | 8.6% | 7.7% | 8.2% | 8.7% | 10.8% | | 9.9% |
|
Diluted EPS | $4.39 | $5.93 | $4.44 | $5.22 | $5.39 | $5.31 | $2.03 | $4.79 |
Shares outstanding (diluted) | 236.1 | 239.4 | 237.9 | 238.2 | 245.4 | 257.8 | 267.4 | 273.6 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|